Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 9
2021 4
2022 1
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Current evidence on the use of anakinra in COVID-19.
Khani E, Shahrabi M, Rezaei H, Pourkarim F, Afsharirad H, Solduzian M. Khani E, et al. Int Immunopharmacol. 2022 Oct;111:109075. doi: 10.1016/j.intimp.2022.109075. Epub 2022 Jul 20. Int Immunopharmacol. 2022. PMID: 35905562 Free PMC article. Review.
Anakinra is the first recombinant IL-1 receptor antagonist studied for off-label use in COVID-19 treatment. This study reviews the current clinical evidence on the role of interleukin-1 in COVID-19-related cytokine storm, th …
Anakinra is the first recombinant IL-1 receptor antagonist studied for off-label use in COVID-19 treatmen …
Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper.
Gelincik A, Brockow K, Çelik GE, Doña I, Mayorga C, Romano A, Soyer Ö, Atanaskovic-Markovic M, Barbaud A, Torres MJ. Gelincik A, et al. Allergy. 2020 Nov;75(11):2775-2793. doi: 10.1111/all.14439. Epub 2020 Jul 1. Allergy. 2020. PMID: 32511784 Free PMC article.
Coronavirus disease 2019 (COVID-19), a respiratory tract infection caused by a novel human coronavirus, the severe acute respiratory syndrome coronavirus 2, leads to a wide spectrum of clinical ma …
Coronavirus disease 2019 (COVID-19), a respiratory tract infection caused by a novel human coronavirus …
Pharmacotherapy in COVID-19; A narrative review for emergency providers.
Mehta N, Mazer-Amirshahi M, Alkindi N, Pourmand A. Mehta N, et al. Am J Emerg Med. 2020 Jul;38(7):1488-1493. doi: 10.1016/j.ajem.2020.04.035. Epub 2020 Apr 15. Am J Emerg Med. 2020. PMID: 32336586 Free PMC article. Review.
With the rapid transmission of disease, even the off-label use of available therapies has been impeded by limited availability. ...PubMed and SCOPUS were queried using a combination of the keywords "COVID 19," "SARS-CoV-2 …
With the rapid transmission of disease, even the off-label use of available therapies has been impeded by limite …
Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19).
Dixon DL, Van Tassell BW, Vecchié A, Bonaventura A, Talasaz AH, Kakavand H, D'Ascenzo F, Perciaccante A, Castagno D, Ammirati E, Biondi-Zoccai G, Stevens MP, Abbate A. Dixon DL, et al. J Cardiovasc Pharmacol. 2020 May;75(5):359-367. doi: 10.1097/FJC.0000000000000836. J Cardiovasc Pharmacol. 2020. PMID: 32282502 Free PMC article. Review.
A novel betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly across the globe since December 2019. Coronavirus disease 2019 (COVID-19) ha …
A novel betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-Co …
Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP).
Bassetti M, Giacobbe DR, Aliberti S, Barisione E, Centanni S, De Rosa FG, Di Marco F, Gori A, Granata G, Mikulska M, Petrosillo N, Richeldi L, Santus P, Tascini C, Vena A, Viale P, Blasi F; Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Bassetti M, et al. Clin Microbiol Infect. 2020 Jul;26(7):880-894. doi: 10.1016/j.cmi.2020.04.031. Epub 2020 Apr 29. Clin Microbiol Infect. 2020. PMID: 32360444 Free PMC article. Review.
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which has rapidly become epidemic in Italy and other …
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is t …
Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients.
Itani R, Tobaiqy M, Al Faraj A. Itani R, et al. Theranostics. 2020 May 1;10(13):5932-5942. doi: 10.7150/thno.46691. eCollection 2020. Theranostics. 2020. PMID: 32483428 Free PMC article. Review.
On the 30(th) of January 2020, the World Health Organization fired up the sirens against a fast spreading infectious disease caused by a newly discovered Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV …
On the 30(th) of January 2020, the World Health Organization fired up the sirens against a fast spreading infectious disease c …
Use of 5% Topical Minoxidil Application for Telogen Effluvium: An Open-Label Single-Arm Clinical Trial.
Ohyama M, Irisawa R, Uchiyama M, Mori M, Aoki K, Ueda Y, Fujita T. Ohyama M, et al. J Dermatol. 2025 Sep;52(9):1351-1359. doi: 10.1111/1346-8138.17844. Epub 2025 Jul 2. J Dermatol. 2025. PMID: 40599040 Free PMC article. Clinical Trial.
Recently, TE attracts global interest as a major cause of hair loss as a sequela of COVID-19. Typically, hair shedding in TE is expected to cease around 3-6 months from the onset with spontaneous hair regrowth, once the triggering factor is eliminated. ...Considerin …
Recently, TE attracts global interest as a major cause of hair loss as a sequela of COVID-19. Typically, hair shedding in TE i …
Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic.
Carron J, Sharif Z, Hussein H, Kennedy M, McAdam B, Sheahan R. Carron J, et al. Ir J Med Sci. 2021 Feb;190(1):403-409. doi: 10.1007/s11845-020-02291-7. Epub 2020 Jul 6. Ir J Med Sci. 2021. PMID: 32627127 Free PMC article. Review.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for coronavirus disease 19 (COVID-19), has rapidly spread since December 2019 to become the focus of hea …
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible …
Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients: A single center experience.
Birlutiu V, Birlutiu RM, Chicea L. Birlutiu V, et al. Medicine (Baltimore). 2021 May 7;100(18):e25832. doi: 10.1097/MD.0000000000025832. Medicine (Baltimore). 2021. PMID: 33950993 Free PMC article.
The primary objective of our study was to establish the effectiveness of TCZ in patients with severe or critical severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pneumonia.We retrospectively analyzed 25 co …
The primary objective of our study was to establish the effectiveness of TCZ in patients with severe or critical severe acute …
SAveRUNNER: an R-based tool for drug repurposing.
Fiscon G, Paci P. Fiscon G, et al. BMC Bioinformatics. 2021 Mar 23;22(1):150. doi: 10.1186/s12859-021-04076-w. BMC Bioinformatics. 2021. PMID: 33757425 Free PMC article.
BACKGROUND: Currently, no proven effective drugs for the novel coronavirus disease COVID-19 exist and despite widespread vaccination campaigns, we are far short from herd immunity. ...CONCLUSIONS: The algorithm was successfully applied to …
BACKGROUND: Currently, no proven effective drugs for the novel coronavirus disease COVID-19 exist …
14 results